summary: This study estimates current costs and quality of life (utility) of patients treated with disease modifying drugs (DMDs) in the United States, and investigates the effect of disease severity on costs and utility. Consistent with other studies, costs and utilities are significantly correlated with functional capacity. The proportion of costs represented by disease modifying drugs is considerably lower than estimated in other studies, as all costs related to the disease are included.

authors: Kobelt G, Berg J, Atherly D, Hadjimichael O.

source: Neurology. 2006 Jun 13;66(11):1696-702.

weblink: click here

category: Epidemiology

related research news: click here

glossary: